Cart
sales@molnova.com
Atuzabrutinib
CAS No. 1581714-49-9
Atuzabrutinib( —— )
Catalog No. M35090 CAS No. 1581714-49-9
Atuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 287 | In Stock |
|
| 5MG | 455 | In Stock |
|
| 10MG | 753 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 2438 | In Stock |
|
| 100MG | 3717 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAtuzabrutinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionAtuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.
-
DescriptionAtuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling.
-
In Vitro——
-
In VivoPRN473 (20 mg/kg) significantly reduces intravascular crawling and neutrophil recruitment into inflamed tissue in a model of sterile liver injury, down to levels seen in Btk-deficient animals.
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1581714-49-9
-
Formula Weight539.6
-
Molecular FormulaC30H30FN7O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (185.32 mM; Ultrasonic )
-
SMILESNC1=C2C(N(N=C2C3=C(F)C=C(OC4=CC=CC=C4)C=C3)[C@H]5CN(C(/C(=C/C(C)(C)C)/C#N)=O)CCC5)=NC=N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Herter JM, et al. PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling. Br J Pharmacol. 2018;175(3):429-439. ?
molnova catalog
related products
-
Pirtobrutinib
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations.
-
(R)-Zanubrutinib
(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).
-
Tirabrutinib
A potent, selective, third-generation irreversible inhibitor of mutant EGFR.
